Terms: = Gastric cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Clinical Outcome
15 results:
1. Identifying immune cells-related phenotype to predict immunotherapy and clinical outcome in gastric cancer.
Jiang S; Ding X; Wu Q; Cheng T; Xu M; Huang J
Front Immunol; 2022; 13():980986. PubMed ID: 36032097
[TBL] [Abstract] [Full Text] [Related]
2. Essential Roles of TDO2 in gastric cancer: TDO2 Is Associated with cancer Progression, Patient Survival, pd-l1 Expression, and cancer Stem Cells.
Pham QT; Taniyama D; Akabane S; Takashima T; Maruyama R; Sekino Y; Sentani K; Yasui W; Oue N
Pathobiology; 2023; 90(1):44-55. PubMed ID: 35679834
[TBL] [Abstract] [Full Text] [Related]
3. Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis.
Xing X; Shi J; Jia Y; Dou Y; Li Z; Dong B; Guo T; Cheng X; Li X; Du H; Hu Y; Jia S; Zhang J; Li Z; Ji J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35361730
[TBL] [Abstract] [Full Text] [Related]
4. The crosstalk between H. pylori virulence factors and the PD1:pd-l1 immune checkpoint inhibitors in progression to gastric cancer.
Aydın EM; Demir TD; Seymen N; Said SS; Oktem-Okullu S; Tiftikci A; Cicek B; Tokat F; Tozun N; Ince U; Sezerman U; Sayi-Yazgan A
Immunol Lett; 2021 Nov; 239():1-11. PubMed ID: 34363898
[TBL] [Abstract] [Full Text] [Related]
5. Predictive value of NLR, TILs (CD4+/CD8+) and pd-l1 expression for prognosis and response to preoperative chemotherapy in gastric cancer.
Zurlo IV; Schino M; Strippoli A; Calegari MA; Cocomazzi A; Cassano A; Pozzo C; Di Salvatore M; Ricci R; Barone C; Bria E; Tortora G; Larocca LM; Basso M; Martini M
Cancer Immunol Immunother; 2022 Jan; 71(1):45-55. PubMed ID: 34009410
[TBL] [Abstract] [Full Text] [Related]
6. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
Saito R; Sawada Y; Nakamura M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410
[TBL] [Abstract] [Full Text] [Related]
7. Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms.
Liverani C; Bongiovanni A; Mercatali L; Pieri F; Spadazzi C; Miserocchi G; Di Menna G; Foca F; Ravaioli S; De Vita A; Cocchi C; Rossi G; Recine F; Ibrahim T
Endocr Pathol; 2021 Jun; 32(2):309-317. PubMed ID: 33409812
[TBL] [Abstract] [Full Text] [Related]
8. Better prognosis of gastric cancer patients with high levels of tumor infiltrating lymphocytes is counteracted by PD-1 expression.
Pötzsch M; Berg E; Hummel M; Stein U; von Winterfeld M; Jöhrens K; Rau B; Daum S; Treese C
Oncoimmunology; 2020 Sep; 9(1):1824632. PubMed ID: 33101772
[TBL] [Abstract] [Full Text] [Related]
9. Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis.
Park R; Lopes L; Saeed A
Clin Transl Oncol; 2021 Jan; 23(1):100-109. PubMed ID: 32495269
[TBL] [Abstract] [Full Text] [Related]
10. Epstein-Barr virus-encoded miR-BART5-5p upregulates pd-l1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of pd-l1-positive gastric carcinomas.
Yoon CJ; Chang MS; Kim DH; Kim W; Koo BK; Yun SC; Kim SH; Kim YS; Woo JH
Gastric Cancer; 2020 Sep; 23(5):780-795. PubMed ID: 32206940
[TBL] [Abstract] [Full Text] [Related]
11. Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous pd-l1 expression in gastric cancer.
Lin C; He H; Liu H; Li R; Chen Y; Qi Y; Jiang Q; Chen L; Zhang P; Zhang H; Li H; Zhang W; Sun Y; Xu J
Gut; 2019 Oct; 68(10):1764-1773. PubMed ID: 30661053
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic Impact of Immune-Related Gene Expression in Preoperative Peripheral Blood from gastric cancer Patients.
Ito S; Fukagawa T; Noda M; Hu Q; Nambara S; Shimizu D; Kuroda Y; Eguchi H; Masuda T; Sato T; Katai H; Sasako M; Mimori K
Ann Surg Oncol; 2018 Nov; 25(12):3755-3763. PubMed ID: 30203407
[TBL] [Abstract] [Full Text] [Related]
13. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and gastric Adenocarcinoma.
Salem ME; Puccini A; Xiu J; Raghavan D; Lenz HJ; Korn WM; Shields AF; Philip PA; Marshall JL; Goldberg RM
Oncologist; 2018 Nov; 23(11):1319-1327. PubMed ID: 29866946
[TBL] [Abstract] [Full Text] [Related]
14. A Four-Factor Immunoscore System That Predicts clinical outcome for Stage II/III gastric cancer.
Wen T; Wang Z; Li Y; Li Z; Che X; Fan Y; Wang S; Qu J; Yang X; Hou K; Zhou W; Xu L; Li C; Wang J; Liu J; Chen L; Zhang J; Qu X; Liu Y
Cancer Immunol Res; 2017 Jul; 5(7):524-534. PubMed ID: 28619967
[TBL] [Abstract] [Full Text] [Related]
15. Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer.
Dai C; Geng R; Wang C; Wong A; Qing M; Hu J; Sun Y; Lo AW; Li J
Mol Oncol; 2016 Dec; 10(10):1551-1558. PubMed ID: 27720576
[TBL] [Abstract] [Full Text] [Related]
